Collegiate Hockey Player Diagnosed with Hodgkin's

The Wall Street Journal is reporting that Hamilton, NY-based Colgate University defenseman Spiro Goulakos has been diagnosed with Hodgkin's lymphoma.

Goulakos, a 6'2" 185 lb sophomore from Montreal who previously played in the Quebec Junior AAA Hockey League, has temporarily left the team and university for treatment in his hometown.

According to Colgate coach Don Vaughan, the news was received with shock by the team and the staff, calling the prior week "very emotional" for all involved.

One would expect Goulakos to undergo between four and eight cycles of chemotherapy, most likely ABVD, the current standard of care for Hodgkin's. The report indicates that Goulakos is expected to make a complete recovery and be back on the Hamilton campus for the fall semester.

The diagnosis was initially suspected following the results of a routine exam.

Hodgkin's is a highly treatable and often curable cancer of the B-cell lymphocytes. When found in its earliest stages, the rigorous treatment can cure as many as nine in 10 patients.

Source: WSJ

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap